AbbVie's Rinvoq Shows Trial Success Amid Dividend Sustainability Concerns

Key Facts

1AbbVie announced positive Phase 3 trial results for Rinvoq in treating non-segmental vitiligo, showing sustained repigmentation.

2Concerns were raised regarding dividend sustainability due to a high payout ratio of 85%.

AbbVie announced positive Phase 3 trial results for its drug Rinvoq in treating non-segmental vitiligo, demonstrating sustained repigmentation in patients. GuruFocus reported that the clinical data supports the efficacy of the treatment, marking a significant development for the company's immunology portfolio.

ABBV closed at $261.59 on September 30, 2026, as investors weigh clinical success against fundamental risks, including a high dividend payout ratio of 85%. The stock reached a day high of $265.36 during the same session, though analysts expressed caution regarding its current valuation and the long-term sustainability of dividend growth.